Teva PharmaceuticalsTEVA
TEVA
About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Employees: 35,686
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
111% more first-time investments, than exits
New positions opened: 95 | Existing positions closed: 45
81% more call options, than puts
Call options by funds: $727M | Put options by funds: $402M
31% more capital invested
Capital invested by funds: $11.2B [Q3] → $14.7B (+$3.43B) [Q4]
29% more funds holding in top 10
Funds holding in top 10: 28 [Q3] → 36 (+8) [Q4]
7% more funds holding
Funds holding: 533 [Q3] → 569 (+36) [Q4]
2.7% more ownership
Funds ownership: 55.99% [Q3] → 58.69% (+2.7%) [Q4]
2% more repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 187
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
47%
upside
Avg. target
$24
78%
upside
High target
$27
98%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Jason Gerberry 26% 1-year accuracy 5 / 19 met price target | 47%upside $20 | Buy Maintained | 6 Mar 2025 |
UBS Ashwani Verma 5% 1-year accuracy 1 / 19 met price target | 98%upside $27 | Buy Maintained | 30 Jan 2025 |
Barclays Balaji Prasad 18% 1-year accuracy 8 / 44 met price target | 90%upside $26 | Overweight Maintained | 30 Jan 2025 |
Financial journalist opinion
Based on 11 articles about TEVA published over the past 30 days
Positive
24/7 Wall Street
4 days ago
Billionaire Sold Broadcom And Bought This Stock That Could Soar 121%
TEVA has 121% upside from its share price today. Retiring early is possible, and may be easier than you think.
Positive
The Motley Fool
1 week ago
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility
For more than a century, the stock market has been the premier wealth creator for investors. But this doesn't mean stocks move higher in a straight line.
Neutral
CNBC Television
1 week ago
BMO's Siegerman talks the impact of tariffs on pharmaceutical stocks
Evan Seigerman, BMO, joins 'Fast Money' to talk the impact of tariffs on pharma space.
Negative
Seeking Alpha
1 week ago
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.
Negative
Investors Business Daily
1 week ago
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports
Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take direct aim at drug imports. The post Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
1 week ago
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine Prevention
PARSIPPANY, N.J. and TEL AVIV, April 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for AJOVY® (fremanezumab-vfrm) to expand the indication to include the prevention of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. If approved, AJOVY would be the only calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address the high unmet need for effective treatments for those living with migraine.
Neutral
GlobeNewsWire
2 weeks ago
New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable
PARSIPPANY, N.J. and TEL AVIV, Israel, March 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) evaluating TEV-'749. More than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about TEV-'749, overall, including initiation regimen, monthly dosing schedule and dosing options.1 The data were presented at the 2025 Congress of the Schizophrenia International Research Society (SIRS) taking place from March 29 to April 2, 2025, in Chicago, IL.
Neutral
The Motley Fool
3 weeks ago
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of Now
It's hard to believe, but the first quarter of 2025 is rapidly coming to a close. After doing a quick portfolio checkup, I found that I have stocks that have gained as much as 40% already this year, but I also have a few that are down nearly 30%.
Neutral
GlobeNewsWire
3 weeks ago
Teva Releases Q1 2025 Aide Memoire
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website.
Neutral
GlobeNewsWire
3 weeks ago
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025
TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
Charts implemented using Lightweight Charts™